TrialLineage Lineage

Phase 3 · Active

RNA-targeted therapy for Angelman syndrome

How UBE3A biology and antisense oligonucleotides led to a Phase 3 rare-disease trial

This lineage starts with an investigational antisense oligonucleotide in a Phase 3 clinical trial for Angelman syndrome, then traces backward through the scientific lineage that made it possible: UBE3A biology, maternal imprinting, antisense transcript regulation, RNA-targeted chemistry, CNS delivery, and rare-disease trial design.

This case page is in development. Content is based on public trial records and published research. Trial outcomes are not yet available.

Trial anchor

REVEAL: Phase 3 study of ION582 in Angelman syndrome

Trial name

REVEAL

NCT ID

NCT06914609

Phase

Phase 3

Disease

Angelman syndrome

Intervention

ION582 (obudanersen)

Modality

Antisense oligonucleotide (ASO)

Sponsor

Ionis Pharmaceuticals

Route

Intrathecal injection

Source

ClinicalTrials.gov

Plain-language summary

What this trial is testing

Angelman syndrome is a rare genetic condition that causes severe developmental delays, movement and balance problems, seizures, and limited speech. It is caused by loss of function of the maternal copy of the UBE3A gene. In most neurons, only the maternal copy of UBE3A is active — the paternal copy is silenced by a long antisense RNA transcript.

ION582 (obudanersen) is an investigational antisense oligonucleotide designed to reduce the expression of the UBE3A antisense transcript (UBE3A-ATS) in neurons. If the antisense transcript is reduced, the hypothesis is that the intact paternal copy of UBE3A can become active, partially restoring UBE3A protein production in the brain.

The REVEAL trial is a Phase 3 study evaluating whether ION582 improves developmental outcomes in children with Angelman syndrome caused by a deletion of the maternal 15q11-q13 region. The drug is administered by intrathecal injection (into the spinal fluid) to reach the central nervous system.

This trial has not yet reported results. Whether the approach produces clinically meaningful benefit remains to be determined.

The disease problem

Angelman syndrome

Angelman syndrome affects approximately 1 in 12,000 to 20,000 people. It is a neurodevelopmental disorder characterized by severe intellectual disability, minimal or absent speech, motor impairment (including ataxia and tremor), seizures, and a characteristic behavioral profile including frequent smiling and easily provoked laughter.

The condition is caused by loss of functional UBE3A expression in neurons. In most cases (~70%), this results from a de novo deletion of the maternal 15q11.2-q13 chromosomal region. Other genetic mechanisms include UBE3A point mutations, paternal uniparental disomy, and imprinting defects.

UBE3A encodes an E3 ubiquitin ligase involved in protein degradation and synaptic function. In most tissues, both parental copies are expressed. In neurons, however, UBE3A is subject to genomic imprinting: only the maternal allele is expressed, while the paternal allele is silenced by the UBE3A antisense transcript (UBE3A-ATS). When the maternal copy is lost or non-functional, neurons have no source of UBE3A protein.

There are currently no approved treatments that address the underlying molecular cause of Angelman syndrome. Existing management is supportive — controlling seizures, managing behavioral symptoms, and providing physical and speech therapy.

Scientific lineage

The chain of discovery behind this trial

The path from basic biology to this Phase 3 trial spans multiple fields and several decades of work.

1965–1987

Clinical recognition and chromosomal mapping

Harry Angelman described the syndrome in 1965. By the late 1980s, cytogenetic studies identified deletions in chromosome 15q11-q13 as the common genetic cause. The observation that only maternal deletions caused the syndrome introduced the concept of genomic imprinting in this region.

1997

UBE3A identified as the causative gene

Multiple groups demonstrated that UBE3A mutations were sufficient to cause Angelman syndrome, and that the gene was subject to brain-specific maternal-only expression (imprinting). This established UBE3A as the molecular target.

2005–2012

Antisense transcript biology

Research revealed that paternal UBE3A silencing in neurons is mediated by a long non-coding antisense transcript (UBE3A-ATS) originating from the SNURF-SNRPN locus. This created a therapeutic hypothesis: reducing UBE3A-ATS might “unsilence” the paternal UBE3A allele.

2012–2015

Preclinical proof of concept

Studies in mouse models of Angelman syndrome demonstrated that antisense oligonucleotides targeting UBE3A-ATS could partially restore paternal UBE3A expression in neurons and improve some disease-related phenotypes. These findings established the biological rationale for ASO-mediated unsilencing.

Enabling platform

Antisense oligonucleotide technology

The broader ASO platform — developed over decades at Ionis Pharmaceuticals and elsewhere — provided the chemistry (modified nucleotides for stability and potency), pharmacology (CNS distribution after intrathecal delivery), and manufacturing infrastructure needed to advance a clinical candidate. Prior successes including nusinersen (Spinraza) for spinal muscular atrophy demonstrated that intrathecal ASOs could reach CNS targets in humans.

2020–present

Clinical development

ION582 (obudanersen) entered clinical testing. Earlier-phase studies assessed safety and tolerability in children with Angelman syndrome. Based on those findings, the REVEAL Phase 3 trial (NCT06914609) was initiated to evaluate efficacy in a larger, controlled cohort.

Known vs. unknown

What the evidence says and what remains open

Established

  • Angelman syndrome is caused by loss of neuronal UBE3A expression
  • The paternal UBE3A allele is silenced in neurons by UBE3A-ATS
  • ASOs targeting UBE3A-ATS can restore paternal UBE3A expression in animal models
  • Intrathecal ASO delivery to the CNS is technically feasible (demonstrated with nusinersen)
  • ION582 has undergone earlier-phase clinical evaluation
  • A Phase 3 trial (REVEAL) is active

Not yet known

  • Whether ION582 produces clinically meaningful improvement in developmental outcomes
  • Whether restored UBE3A expression is sufficient to reverse established neurodevelopmental deficits
  • The optimal timing of intervention (age at treatment initiation)
  • Long-term safety profile of chronic intrathecal ASO administration in children
  • Whether benefit varies by genotype (deletion vs. other mechanisms)
  • Whether partial UBE3A restoration translates to functional improvement

TrialLineage interpretation

What this story shows

The following is editorial interpretation by TrialLineage, not a statement of clinical fact.

This case illustrates how understanding a gene-regulation mechanism can lead to a therapeutic hypothesis in a rare genetic disease. The logic is specific: the paternal UBE3A allele is intact but silenced; the silencing mechanism is a readable antisense transcript; ASO technology can target that transcript; therefore ASO-mediated unsilencing is a rationally designed intervention.

The lineage also demonstrates the role of platform technology: ION582 exists because decades of prior work on antisense chemistry, CNS delivery, and manufacturing created a mature delivery infrastructure. The success of nusinersen in spinal muscular atrophy validated the intrathecal ASO approach and de-risked the delivery route for other CNS conditions.

Whether this rational biological hypothesis translates into clinical benefit for patients with Angelman syndrome is the question the REVEAL trial is designed to answer.

Platform context

RNA medicine as a broader platform

ION582 / obudanersen is one of many RNA-targeted therapies in clinical development. The broader RNA medicine platform includes antisense oligonucleotides, small interfering RNAs (siRNAs), exon skipping approaches, and splicing modulators — each addressing different genetic mechanisms across different diseases.

TrialLineage treats RNA medicine as a platform lineage, not a single case. This page focuses specifically on the Angelman syndrome trial. Other RNA-based rare-disease trials may become separate TrialLineage lineages as the platform expands.

Source

Trial record

ClinicalTrials.gov — NCT06914609: REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome.

The scientific lineage on this page draws on published research in human genetics, molecular biology, and clinical neuroscience.